Funding Achievement for Biological Lattice Industries
Biological Lattice Industries Corp. (BLI), recognized as a significant innovator in the biofabrication and life sciences research and development sectors, has recently announced a successful closing of a $1.8 million pre-seed investment round. This funding was led by the Greek venture capital firm Uni.Fund.
Introducing BioLoom™ and Loominus Studio™
In conjunction with this funding announcement, BLI is excited to unveil its first all-in-one solution for biofabrication: BioLoom™, complemented by Loominus Studio™, an integrated software platform. Together, these innovative tools are set to reshape the biofabrication landscape.
Transforming Biofabrication with Innovative Solutions
BLI, a startup with research and development operations located in Greece, has a mission to greatly simplify biofabrication processes for the global research community. By providing intelligent automated tools, BLI enables the design, fabrication, and testing of biomaterials to be streamlined from start to finish.
The Importance of Biomaterials in Healthcare
Biomaterials are essential across various biological applications. These applications can include advanced 3D cell culture systems that replicate human biology and the development of next-generation medical devices that are resorbable. Moreover, these biomaterials are crucial in drug delivery systems, particularly for tissue trauma repair.
Vision for the Future: Enhancing Research Through Automation
“We are thrilled to partner with Uni.Fund to bring our vision of democratizing biofabrication to life,” remarked Filippos Tourlomousis, Founder and Chief Executive Officer of BLI. “This funding will facilitate the enhancement of our unified platform, helping researchers achieve greater precision and efficiency,” he added.
Loominus Studio: The Future of Integrated Workflows
Current biofabrication methods often involve multiple disparate systems that lack integration, leading to inefficiencies. Loominus Studio™ addresses this issue by uniting all facets of the biofabrication workflow—from design to fabrication. This comprehensive solution empowers researchers to automate complex processes, drive reproducibility, and lessen the burden of optimizing biofabrication methodologies.
BioLoom™: Pioneering Advances in 3D Bioprinting
At the core of BLI’s ecosystem is BioLoom™, a powerful multi-tool extrusion-based 3D bioprinter. This cutting-edge device is capable of fabricating high-resolution, multi-material scaffolds and medical devices. With features such as Active Environmental Control, BioLoom ensures consistent output while supporting Good Manufacturing Practice (GMP) compliance, making it a valuable asset for labs that prioritize swift commercialization in life sciences.
A Commitment to Innovation
“BioLoom provides unmatched versatility and precision,” stated Tourlomousis. “It is crafted to fulfill the demands of both academic and commercial laboratories, pushing the boundaries of biofabrication beyond conventional 3D bioprinting capabilities,” he continued.
Partnership with Uni.Fund: A Leap Forward
Uni.Fund, known for its dedication to supporting top-tier deep tech startups in Europe, views BLI as a transformative force within the biofabrication sector. Katerina Pramatari, Founding Partner at Uni.Fund, noted, “BLI is a game-changer in biotechnology, with an inspiring vision to radically alter biofabrication practices around the world.”
Setting New Standards for Biofabrication
With its ambitious goals, BLI is determined to position Loominus as the industry benchmark in biofabrication laboratories, delivering a constantly expanding range of tools and features aimed at simplifying intricate workflows. The new investment will aid in accelerating the market release of both BioLoom and Loominus Studio, which have already been implemented in several leading academic laboratories through the company's early adopter program.
About Biological Lattice Industries (BLI)
Biological Lattice Industries Corp. (BLI) is an innovative and venture-backed startup founded with a mission to democratize biofabrication across the life sciences R&D landscape. BLI's integrated platform, Loominus Studio, along with its suite of hardware tools, including the BioLoom bioprinter, is designed to revolutionize how biomaterials are developed, produced, and tested.
Frequently Asked Questions
What is Biological Lattice Industries (BLI)?
Biological Lattice Industries, or BLI, is a startup focused on biofabrication and life sciences, providing innovative solutions for biomaterials.
What does the recent funding mean for BLI?
The $1.8 million pre-seed funding will accelerate the development of BLI's innovative platforms and tools for biofabrication.
What products are introduced by BLI?
BLI has introduced BioLoom™, an advanced multi-tool 3D bioprinter, and Loominus Studio™, a comprehensive software platform for biofabrication.
How does BioLoom™ improve biofabrication?
BioLoom™ enhances biofabrication by providing high precision and versatility, allowing labs to create advanced biomaterials efficiently.
What is the vision of BLI regarding biofabrication?
BLI aims to democratize biofabrication by creating user-friendly tools that simplify complex workflows, empowering researchers worldwide.
